SG10201402867TA - Novel (6-oxo-1, 6-dihydro-pyrimidin-2-yl)-amide derivatives, preparation thereof, and pharmaceutical use thereof as akt(pkb) phosphorylation inhibitors - Google Patents

Novel (6-oxo-1, 6-dihydro-pyrimidin-2-yl)-amide derivatives, preparation thereof, and pharmaceutical use thereof as akt(pkb) phosphorylation inhibitors

Info

Publication number: SG10201402867TA
Authority: SG; Singapore
Prior art keywords: pkb; akt; pyrimidin; dihydro; oxo
Prior art date: 2009-07-02

Application number

SG10201402867TA

Other languages

English (en)

Original Assignee

Sanofi Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-07-02

Filing date

2010-07-01

Publication date

2014-08-28

2009-07-02 Priority claimed from FR0903239A external-priority patent/FR2947547B1/fr

2009-10-09 Priority claimed from FR0957070A external-priority patent/FR2951169B1/fr

2010-07-01 Application filed by Sanofi Sa filed Critical Sanofi Sa

2014-08-28 Publication of SG10201402867TA publication Critical patent/SG10201402867TA/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

SG10201402867TA 2009-07-02 2010-07-01 Novel (6-oxo-1, 6-dihydro-pyrimidin-2-yl)-amide derivatives, preparation thereof, and pharmaceutical use thereof as akt(pkb) phosphorylation inhibitors SG10201402867TA (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
FR0903239A FR2947547B1 (fr)	2009-07-02	2009-07-02	Nouveaux derives de (6-oxo-1,6-dihydro-pyrimidin-2-yl)-amide, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt (pkb)
US24110009P	2009-09-10	2009-09-10
FR0957070A FR2951169B1 (fr)	2009-10-09	2009-10-09	Nouveaux derives de (6-oxo-1,6-dihydro-pyrimidin-2-yl)-amide, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)

Publications (1)

Publication Number	Publication Date
SG10201402867TA true SG10201402867TA (en)	2014-08-28

Family

ID=42635553

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
SG2011097938A SG177469A1 (en)	2009-07-02	2010-07-01	Novel (6-oxo-1, 6-dihydro-pyrimidin-2-yl)-amide derivatives, preparation thereof, and pharmaceutical use thereof as akt(pkb) phosphorylation inhibitors
SG10201402867TA SG10201402867TA (en)	2009-07-02	2010-07-01	Novel (6-oxo-1, 6-dihydro-pyrimidin-2-yl)-amide derivatives, preparation thereof, and pharmaceutical use thereof as akt(pkb) phosphorylation inhibitors

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
SG2011097938A SG177469A1 (en)	2009-07-02	2010-07-01	Novel (6-oxo-1, 6-dihydro-pyrimidin-2-yl)-amide derivatives, preparation thereof, and pharmaceutical use thereof as akt(pkb) phosphorylation inhibitors

Country Status (37)

Country	Link
US (2)	US8791255B2 (fr)
EP (1)	EP2448927B1 (fr)
JP (1)	JP5680638B2 (fr)
KR (1)	KR20120106714A (fr)
CN (1)	CN102548970B (fr)
AR (1)	AR077364A1 (fr)
AU (1)	AU2010267816B2 (fr)
CA (1)	CA2767064C (fr)
CL (1)	CL2012000003A1 (fr)
CO (1)	CO6480974A2 (fr)
CR (1)	CR20110703A (fr)
DK (1)	DK2448927T3 (fr)
DO (1)	DOP2011000407A (fr)
EA (1)	EA021088B1 (fr)
EC (1)	ECSP12011570A (fr)
ES (1)	ES2464125T3 (fr)
HK (1)	HK1169110A1 (fr)
HN (1)	HN2011003482A (fr)
HR (1)	HRP20140478T1 (fr)
IL (2)	IL217295A (fr)
MA (1)	MA33501B1 (fr)
ME (1)	ME01885B (fr)
MX (1)	MX2012000094A (fr)
MY (1)	MY153042A (fr)
NI (1)	NI201200002A (fr)
NZ (1)	NZ597579A (fr)
PE (1)	PE20120640A1 (fr)
PL (1)	PL2448927T3 (fr)
PT (1)	PT2448927E (fr)
RS (1)	RS53317B (fr)
SG (2)	SG177469A1 (fr)
SI (1)	SI2448927T1 (fr)
SM (1)	SMT201400084B (fr)
TW (1)	TWI466883B (fr)
UY (1)	UY32755A (fr)
WO (1)	WO2011001114A1 (fr)
ZA (1)	ZA201200026B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2658844B1 (fr) *	2010-12-28	2016-10-26	Sanofi	Nouveaux derives de pyrimidines, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)
FR2969614A1 (fr) *	2010-12-28	2012-06-29	Sanofi Aventis	Nouveaux derives de pyrimidinones, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)
FR2969609B1 (fr) *	2010-12-28	2013-02-08	Sanofi Aventis	Nouveaux derives de 6-oxo-dihydro-pyrimidine, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)
FR2969610B1 (fr) *	2010-12-28	2013-04-05	Sanofi Aventis	Nouveaux derives de (6-oxo-1,6-dihydro-pyrimidin-2-yl)-indolinamide, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)
CA2826387A1 (fr) *	2011-02-11	2012-08-16	Dana Farber Cancer Institute, Inc.	Procede d'inhibition de cellules tumorales d'hamartome
EP2570127A1 (fr) *	2011-09-16	2013-03-20	Sanofi	Compositions et procédés pour traiter le cancer avec un inhibiteur bêta PI3KB et un inhibiteur de la voie MAPK, incluant des inhibiteurs MEK et RAF
CA2904770A1 (fr)	2013-03-15	2014-09-18	Sanofi	Composition antitumorale comprenant un inhibiteur de pi3kbeta et un inhibiteur de raf, pour surmonter la resistance de cellules cancereuses
CN105163736A (zh)	2013-04-05	2015-12-16	赛诺菲	包含PI3Kβ选择性抑制剂和PI3Kα选择性抑制剂的抗肿瘤组合物
CA2966224C (fr)	2014-12-02	2019-05-07	Halliburton Energy Services, Inc.	Vaporiseur de gaz naturel liquefie pour applications de petrole ou de gaz de fond de puits
SG11202104550WA (en)	2018-11-20	2021-05-28	Tes Pharma S R L	INHIBITORS OF a-AMINO-ß-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR023052A1 (es) *	1998-09-25	2002-09-04	Mitsuharu Yoshimura Milton	Derivados de pirimidona
ATE396978T1 (de)	1999-10-07	2008-06-15	Amgen Inc	Triazin-kinase-hemmer
CA2398163C (fr)	2000-01-24	2011-02-22	Kinacia Pty Ltd.	Composes therapeutiques a substitution morpholino
GB0119865D0 (en)	2001-08-14	2001-10-10	Cancer Res Campaign Tech	DNA-PK inhibitors
US7365069B2 (en) *	2002-04-10	2008-04-29	Bexel Pharmaceuticals Inc.	Pyrimidone derivatives
EP1537102A4 (fr)	2002-08-16	2010-12-08	Astrazeneca Ab	Inhibition de la phosphoinositide 3-kinase beta
US20090227587A1 (en) *	2003-10-31	2009-09-10	Warner-Lambert Company Llc	Pyrimidines as inhibitors of phosphoinositide-3-kinases (PI3K)
GB0415365D0 (en)	2004-07-09	2004-08-11	Astrazeneca Ab	Pyrimidine derivatives
AR053358A1 (es)	2005-04-15	2007-05-02	Cancer Rec Tech Ltd	Inhibidores de adn - pk
JP2008542253A (ja)	2005-05-26	2008-11-27	クドスファーマシューティカルズリミテッド	Ｄｎａ損傷癌療法に対してａｔｍ欠損癌を感作するためのｄｎａ−ｐｋ阻害の使用
US7700592B2 (en)	2005-08-25	2010-04-20	Schering Corporation	α2C adrenoreceptor agonists
GB0520657D0 (en)	2005-10-11	2005-11-16	Ludwig Inst Cancer Res	Pharmaceutical compounds
US7745477B2 (en)	2006-02-07	2010-06-29	Hoffman-La Roche Inc.	Heteroaryl and benzyl amide compounds
WO2008064244A2 (fr)	2006-11-20	2008-05-29	The Trustees Of Columbia University In The City Of New York	Modulation des phosphoinositides pour le traitement de maladies neurodégénératives
WO2008148074A2 (fr)	2007-05-24	2008-12-04	Research Foundation Of State University Of New York	Inhibiteurs de mtor et methodes de traitement mettant en œuvre ces inhibiteurs
US8138183B2 (en)	2007-07-09	2012-03-20	Astrazeneca Ab	Morpholino pyrimidine derivatives used in diseases linked to mTOR kinase and/or PI3K
US20100261723A1 (en)	2007-07-09	2010-10-14	Astrazeneca Ab	Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
EP2176256A2 (fr)	2007-07-09	2010-04-21	AstraZeneca AB	Derives de pyrimidine trisubstitues pour le traitement de maladies proliferatives
CA2692945A1 (fr)	2007-07-09	2009-01-15	Astrazeneca Ab	Composes 945
AR074072A1 (es)	2008-11-11	2010-12-22	Lilly Co Eli	Compuesto de imidazol -piperidin -pirrol-pirimidin-6-ona, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar el glioblastoma multiforme
US8283372B2 (en)	2009-07-02	2012-10-09	Tetralogic Pharmaceuticals Corp.	2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic

2010
- 2010-07-01 RS RS20140306A patent/RS53317B/en unknown
- 2010-07-01 CN CN201080039214.XA patent/CN102548970B/zh not_active Expired - Fee Related
- 2010-07-01 EA EA201270111A patent/EA021088B1/ru not_active IP Right Cessation
- 2010-07-01 JP JP2012518120A patent/JP5680638B2/ja not_active Expired - Fee Related
- 2010-07-01 AR ARP100102350A patent/AR077364A1/es unknown
- 2010-07-01 WO PCT/FR2010/051375 patent/WO2011001114A1/fr active Application Filing
- 2010-07-01 NZ NZ597579A patent/NZ597579A/xx not_active IP Right Cessation
- 2010-07-01 ME MEP-2014-62A patent/ME01885B/me unknown
- 2010-07-01 CA CA2767064A patent/CA2767064C/fr not_active Expired - Fee Related
- 2010-07-01 PT PT107420143T patent/PT2448927E/pt unknown
- 2010-07-01 SG SG2011097938A patent/SG177469A1/en unknown
- 2010-07-01 EP EP10742014.3A patent/EP2448927B1/fr active Active
- 2010-07-01 KR KR1020127002839A patent/KR20120106714A/ko not_active Abandoned
- 2010-07-01 SI SI201030607T patent/SI2448927T1/sl unknown
- 2010-07-01 MA MA34593A patent/MA33501B1/fr unknown
- 2010-07-01 DK DK10742014.3T patent/DK2448927T3/da active
- 2010-07-01 AU AU2010267816A patent/AU2010267816B2/en not_active Ceased
- 2010-07-01 MY MYPI2011006377 patent/MY153042A/en unknown
- 2010-07-01 ES ES10742014.3T patent/ES2464125T3/es active Active
- 2010-07-01 MX MX2012000094A patent/MX2012000094A/es active IP Right Grant
- 2010-07-01 PL PL10742014T patent/PL2448927T3/pl unknown
- 2010-07-01 SG SG10201402867TA patent/SG10201402867TA/en unknown
- 2010-07-01 PE PE2012000004A patent/PE20120640A1/es not_active Application Discontinuation
- 2010-07-02 UY UY0001032755A patent/UY32755A/es not_active Application Discontinuation
- 2010-07-02 TW TW99121906A patent/TWI466883B/zh not_active IP Right Cessation
2011
- 2011-12-21 CR CR20110703A patent/CR20110703A/es unknown
- 2011-12-26 DO DO2011000407A patent/DOP2011000407A/es unknown
- 2011-12-27 US US13/338,011 patent/US8791255B2/en not_active Expired - Fee Related
- 2011-12-29 CO CO11180700A patent/CO6480974A2/es active IP Right Grant
- 2011-12-29 IL IL217295A patent/IL217295A/en not_active IP Right Cessation
- 2011-12-30 HN HN2011003482A patent/HN2011003482A/es unknown
2012
- 2012-01-01 IL IL217321A patent/IL217321A0/en unknown
- 2012-01-02 CL CL2012000003A patent/CL2012000003A1/es unknown
- 2012-01-03 ZA ZA2012/00026A patent/ZA201200026B/en unknown
- 2012-01-03 EC EC2012011570A patent/ECSP12011570A/es unknown
- 2012-01-05 NI NI201200002A patent/NI201200002A/es unknown
- 2012-10-05 HK HK12109790.9A patent/HK1169110A1/xx not_active IP Right Cessation
2014
- 2014-05-28 HR HRP20140478AT patent/HRP20140478T1/hr unknown
- 2014-06-23 US US14/312,124 patent/US8993565B2/en not_active Expired - Fee Related
- 2014-06-26 SM SM201400084T patent/SMT201400084B/xx unknown

Also Published As

Publication number	Publication date
DOP2011000407A (es)	2012-06-15
JP2012531464A (ja)	2012-12-10
CN102548970B (zh)	2015-11-25
US8791255B2 (en)	2014-07-29
SMT201400084B (it)	2014-09-08
MA33501B1 (fr)	2012-08-01
CO6480974A2 (es)	2012-07-16
CL2012000003A1 (es)	2012-08-03
DK2448927T3 (da)	2014-06-16
PT2448927E (pt)	2014-06-12
NI201200002A (es)	2012-03-30
NZ597579A (en)	2013-06-28
EA021088B1 (ru)	2015-04-30
HK1169110A1 (en)	2013-01-18
AU2010267816B2 (en)	2015-11-12
AU2010267816A1 (en)	2012-02-16
TW201103924A (en)	2011-02-01
EA201270111A1 (ru)	2012-07-30
PL2448927T3 (pl)	2014-09-30
ZA201200026B (en)	2013-03-27
HN2011003482A (es)	2014-11-10
ME01885B (me)	2014-12-20
CN102548970A (zh)	2012-07-04
CA2767064C (fr)	2017-11-07
ECSP12011570A (es)	2012-02-29
CA2767064A1 (fr)	2011-01-06
MY153042A (en)	2014-12-31
US20120270867A1 (en)	2012-10-25
US20140303156A1 (en)	2014-10-09
EP2448927A1 (fr)	2012-05-09
HRP20140478T1 (hr)	2014-07-04
AR077364A1 (es)	2011-08-24
TWI466883B (zh)	2015-01-01
EP2448927B1 (fr)	2014-03-12
US8993565B2 (en)	2015-03-31
KR20120106714A (ko)	2012-09-26
IL217295A0 (en)	2012-02-29
IL217295A (en)	2015-10-29
JP5680638B2 (ja)	2015-03-04
UY32755A (es)	2011-01-31
PE20120640A1 (es)	2012-06-09
MX2012000094A (es)	2012-05-22
RS53317B (en)	2014-10-31
ES2464125T3 (es)	2014-05-30
CR20110703A (es)	2012-03-06
SG177469A1 (en)	2012-02-28
IL217321A0 (en)	2012-02-29
SI2448927T1 (sl)	2014-06-30
WO2011001114A1 (fr)	2011-01-06

Publication	Publication Date	Title
SG10201402867TA (en)	2014-08-28	Novel (6-oxo-1, 6-dihydro-pyrimidin-2-yl)-amide derivatives, preparation thereof, and pharmaceutical use thereof as akt(pkb) phosphorylation inhibitors
HK1164050A1 (en)	2012-09-21	Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof
IL220863A (en)	2017-11-30	Oxazole derivatives of kinase inhibitors, medicinal preparations containing them and their uses
PL2658844T3 (pl)	2017-04-28	Nowe pochodne pirymidyn, ich wytwarzanie i ich zastosowanie farmaceutyczne jako inhibitorów fosforylacji AKT(pkb)
HK1162352A1 (en)	2012-08-31	Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof -3-
TWI562992B (en)	2016-12-21	Indazole derivative, pharmaceutical composition thereof, and use thereof as inhibitors of kinase activity
IL214175A (en)	2015-09-24	Derivatives of aminotetralin, their pharmaceutical compositions and their use
AP3179A (en)	2015-03-31	Benzofuranyl derivatives used as glucokinase inhibitors
ZA201206223B (en)	2013-04-24	Certain kynurenine-3-monooxygenase inhibitors,pharmaceutical compositions, and methods of use thereof
ZA201202906B (en)	2012-12-27	Novel naphthyridine derivatives and the use thereof as kinase inhibitors
WO2011153157A3 (fr)	2012-04-19	Inhibiteurs benzoquinolone de vmat2
IL224288A (en)	2015-02-26	Derivatives of converted pyrazolamide, pharmaceutical preparations containing them and their use
IL209258A (en)	2017-01-31	Derivatives of Pyrolopyridine, Pharmaceutical Preparations Containing Them, Processes for their Preparation and Uses
IL211018A (en)	2015-11-30	Inhibitors, processes for making them, medicinal preparations containing them and their use
IL206394A (en)	2015-10-29	Derivatives of 2-Benzylpyridine Filtration as Met Kinase Inhibitors, Process for their Preparation, Medication and Use
EP2365809B8 (fr)	2018-10-10	Pyrazinopyrazines et dérivés utiles comme inhibiteurs de kinases
ZA201008387B (en)	2012-02-29	Azacarboline derivatives,preparation thereof,and therapeutic use thereof as kinase inhibitors
IL216113A (en)	2015-02-26	Processed derivatives of indazole and azaza-indazole, pharmaceutical preparations containing them and their uses
EP2447253A4 (fr)	2012-11-14	Composés de dihydropyrimidine et leurs procédés de préparation, leurs compositions pharmaceutiques et leurs utilisations
IL211713A (en)	2015-04-30	History of Anilinopyrimidine Converted to Sulfoxaamine as CDK Inhibitors, Manufactured and Used as Drugs
PT2504331E (pt)	2015-02-20	Composto, novas formas desse composto, composições farmacêuticas desse composto e métodos de preparação e utilização
EP2320738A4 (fr)	2011-08-24	Dérivés d'aminothiazole substitués, compositions pharmaceutiques et leurs procédés d'utilisation
IL214408A0 (en)	2011-09-27	Derivatives of 6-(6-substituted-triazolopyidazine-sulfanyl) 5-fluoro-benzothiazoles and 5-fluoro-benzimidazoles, preparation thereof, use thereof as drugs, and use thereof as met inhibitors
EP2424533A4 (fr)	2012-10-17	Dérivés d'isoquinoline substitués, compositions pharmaceutiques et leurs méthodes d'utilisation en tant qu'inhibiteurs de -sécrétase
ZA201203531B (en)	2013-07-31	Certain crystalline hydrates, pharmaceutical compositions thereof and methods for preparation and use thereof